Developmental Therapeutics Recent Publications

2023

Protein degraders enter the clinic - a new approach to cancer therapy.Chirnomas D, Hornberger KR, Crews CM. Nat Rev Clin Oncol. 2023 Apr; 2023 Feb 13. PMID: 36781982.
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Ann Hematol. 2023 Apr; 2023 Feb 3. PMID: 36732419.
Machine Learning Models for Predicting the Outcomes of Surgical Treatment of Colorectal Liver Metastases.Moaven O, Tavolara TE, Valenzuela CD, Cheung TT, Corvera CU, Cha CH, Stauffer JA, Niazi MKK, Gurcan MN, Shen P. J Am Coll Surg. 2023 Apr 1; 2023 Jan 19. PMID: 36727981.
Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.Dizman N, Austin M, Considine B, Jessel S, Schoenfeld D, Merl MY, Hurwitz M, Sznol M, Kluger H. Clin Genitourin Cancer. 2023 Apr; 2023 Jan 12. PMID: 36681606.
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.Guru Murthy GS, Logan BR, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared JA, Stefanski HE, Pulsipher MA, Hsu JW, Switzer GE, Panch SR, Shaw BE. Am J Hematol. 2023 Apr; 2023 Jan 16. PMID: 36606713.
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ. Transplant Cell Ther. 2023 Apr; 2022 Dec 13. PMID: 36526260.
Preface: Phyto-derived nanomedicines for therapeutics, imaging and drug delivery.Qiao H, Zhang J, Cheng YC. Adv Drug Deliv Rev. 2023 Apr; 2022 Dec 9. PMID: 36503066.
HALO: A software tool for real-time head alignment in the MR scanner.Zhao Z, Galiana G, Zillo C, Camarro T, Qiu M, Papademetris X, Hampson M. Magn Reson Med. 2023 Apr; 2022 Nov 25. PMID: 36426774.
Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood.Qian DC, Ulrich BC, Peng G, Zhao H, Conneely KN, Miller AH, Bruner DW, Eldridge RC, Wommack EC, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Stokes WA, Beitler JJ, Xiao C. Int J Radiat Oncol Biol Phys. 2023 Apr 1; 2022 Nov 21. PMID: 36410685.
Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients.Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Leukemia. 2023 Mar 22; 2023 Mar 22. PMID: 36949156.
Identification of Efflux Substrates Using a Riboswitch-Based Reporter in Pseudomonas aeruginosa.Urdaneta-Páez V, Hamchand R, Anthony K, Crawford J, Sutherland AG, Kazmierczak BI. mSphere. 2023 Mar 22; 2023 Mar 22. PMID: 36946743.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich TMP, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Burton EA, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin AD. Gynecol Oncol. 2023 Mar 21; 2023 Mar 21. PMID: 36958197.
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Oncologist. 2023 Mar 20; 2023 Mar 20. PMID: 36940261.
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence.Shallis RM, Wang R, Zeidan AM, Huntington SF, Neparidze N, Stempel JM, Mendez LM, Di M, Ma X, Podoltsev NA. Blood Adv. 2023 Mar 20; 2023 Mar 20. PMID: 36939371.
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru VG, Xu F, Doebele RC, Hong DS. J Clin Oncol. 2023 Mar 20; 2023 Jan 20. PMID: 36669146.
Bacteria require phase separation for fitness in the mammalian gut.Krypotou E, Townsend GE, Gao X, Tachiyama S, Liu J, Pokorzynski ND, Goodman AL, Groisman EA. Science. 2023 Mar 17; 2023 Mar 16. PMID: 36927025.
Surgery or Endovascular Therapy for Chronic Limb Ischemia.Roberts JD. N Engl J Med. 2023 Mar 16. PMID: 36920767.
Including International Medical Graduates in Diversity, Equity, and Inclusion Conversations Among Pathology Training Programs.Schukow CP, Zeidan AM, Loghavi S. Arch Pathol Lab Med. 2023 Mar 15; 2023 Mar 15. PMID: 36919991.
Design, synthesis, and biological testing of biphenylmethyloxazole inhibitors targeting HIV-1 reverse transcriptase.Carter ZJ, Hollander K, Spasov KA, Anderson KS, Jorgensen WL. Bioorg Med Chem Lett. 2023 Mar 15; 2023 Mar 3. PMID: 36871704.
Percutaneous Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Pain and Ambulatory Function in Periacetabular Osteolytic Malignancies.Dussik CM, Toombs C, Alder KD, Yu KE, Berson ER, Ibe IK, Li F, Lindskog DM, Friedlaender GE, Latich I, Lee FY. Radiology. 2023 Mar 14; 2023 Mar 14. PMID: 36916888.
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM, Forman HP, Huntington SF. Blood Adv. 2023 Mar 14. PMID: 36342852.
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Blood Adv. 2023 Mar 14. PMID: 35917456.
Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion.Chen AT, Xiao Y, Tang X, Baqri M, Gao X, Reschke M, Sheu WC, Long G, Zhou Y, Deng G, Zhang S, Deng Y, Bai Z, Kim D, Huttner A, Kunes R, Günel M, Moliterno J, Saltzman WM, Fan R, Zhou J. Neuro Oncol. 2023 Mar 14. PMID: 35901838.
ASO Visual Abstract: Conditional Survival After Hepatectomy for Colorectal Liver Metastasis-Results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC).Valenzuela CD, Moaven O, Solsky IB, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha CH, Zarandi NP, Dourado J, Perry KC, Russell G, Shen P. Ann Surg Oncol. 2023 Mar 13; 2023 Mar 13. PMID: 36914908.
Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li FY, Neal J, Lemmon MA, Walther Z, Politi K, Goldberg SB. Clin Cancer Res. 2023 Mar 13; 2023 Mar 13. PMID: 36913537.
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1(st) International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Blood Rev. 2023 Mar 11; 2023 Mar 11. PMID: 36934059.
Living donor liver transplant candidate and donor selection and engagement: Meeting report from the living donor liver transplant consensus conference.Jesse MT, Jackson WE, Liapakis A, Ganesh S, Humar A, Goldaracena N, Levitsky J, Mulligan D, Pomfret EA, Ladner DP, Roberts JP, Mavis A, Thiessen C, Trotter J, Winder GS, Griesemer AD, Pillai A, Kumar V, Verna EC, LaPointe Rudow D, Han HH. Clin Transplant. 2023 Mar 9; 2023 Mar 9. PMID: 36892182.
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. N Engl J Med. 2023 Mar 9. PMID: 36884323.
Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90β.Chen SR, Li ZQ, Xu J, Ding MY, Shan YM, Cheng YC, Zhang GX, Sun YW, Wang YQ, Wang Y. Acta Pharmacol Sin. 2023 Mar 7; 2023 Mar 7. PMID: 36882503.
Vascular steal and associated intratumoral aneurysms in highly vascular brain tumors: illustrative case.Hong CS, Marianayagam NJ, Morales-Valero SF, Barak T, Tabor JK, O'Brien J, Huttner A, Baehring J, Gunel M, Erson-Omay EZ, Fulbright RK, Matouk CC, Moliterno J. J Neurosurg Case Lessons. 2023 Mar 6; 2023 Mar 6. PMID: 36880509.
First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?Burtness B. J Clin Oncol. 2023 Mar 6; 2023 Mar 6. PMID: 36877893.
The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.Goldberg SB, Herbst RS. Lancet. 2023 Mar 4; 2023 Feb 9. PMID: 36774937.
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.Atkins MB, Ascierto PA, Feltquate D, Gulley JL, Johnson DB, Khushalani NI, Sosman J, Yap TA, Kluger H, Sullivan RJ, Tawbi H. J Immunother Cancer. 2023 Mar. PMID: 36918225.
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.Kluger H, Barrett JC, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H, Sharon E. J Immunother Cancer. 2023 Mar. PMID: 36918224.
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.Rizvi N, Ademuyiwa FO, Cao ZA, Chen HX, Ferris RL, Goldberg SB, Hellmann MD, Mehra R, Rhee I, Park JC, Kluger H, Tawbi H, Sullivan RJ. J Immunother Cancer. 2023 Mar. PMID: 36918220.
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".Harold J, Bellone S, Manavell DD, Mutlu L, McNamara B, Hartwich TMP, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Santin AD. Gynecol Oncol. 2023 Mar. PMID: 36906375.
Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma.Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. Int J Mol Sci. 2023 Mar 1; 2023 Mar 1. PMID: 36902188.
Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging.Joel MZ, Avesta A, Yang DX, Zhou JG, Omuro A, Herbst RS, Krumholz HM, Aneja S. Cancers (Basel). 2023 Mar 1; 2023 Mar 1. PMID: 36900339.
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.Caulfield JI, Aizenbud L, Perdigoto AL, Meffre E, Jilaveanu L, Michalek DA, Rich SS, Aizenbud Y, Adeniran A, Herold KC, Austin MR, Kluger H. J Immunother Cancer. 2023 Mar. PMID: 36898736.
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. J Natl Compr Canc Netw. 2023 Mar. PMID: 36898362.
Conditional Survival After Hepatectomy for Colorectal Liver Metastasis: Results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC).Valenzuela CD, Moaven O, Solsky IB, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha CH, Pourhabibi Zarandi N, Dourado J, Perry KC, Russell G, Shen P. Ann Surg Oncol. 2023 Mar 1; 2023 Mar 1. PMID: 36859704.
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.McNamara B, Chang Y, Mutlu L, Harold J, Santin AD. Expert Opin Biol Ther. 2023 Mar; 2023 Feb 26. PMID: 36800548.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich TMP, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa MSZ, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Dottino PR, Schwartz PE, Santin AD. Gynecol Oncol. 2023 Mar; 2023 Jan 25. PMID: 36706643.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella DD, Demirkiran C, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Gynecol Oncol. 2023 Mar; 2023 Jan 5. PMID: 36610380.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A, Khan U, King DA, Klute K, Lacy J, Lee JJ, Mehta R, Mukherjee S, Nagarajan A, Park H, Saeed A, Semrad TJ, Shitara K, Smyth E, Uboha NV, Vincelli M, Wainberg Z, Rajdev L. J Clin Oncol. 2023 Mar 1; 2023 Jan 5. PMID: 36603169.
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.Yap TA, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow M. Clin Cancer Res. 2023 Mar 1. PMID: 36342102.
TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.Ball S, Loghavi S, Zeidan AM. Leuk Lymphoma. 2023 Mar; 2022 Nov 2. PMID: 36323304.
Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide.Singh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Pediatr Blood Cancer. 2023 Mar; 2022 Sep 24. PMID: 36151992.
CHIPing away the progression potential of CHIP: A new reality in the making.Xie Z, Zeidan AM. Blood Rev. 2023 Mar; 2022 Aug 15. PMID: 35989137.
Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. J Neurosurg. 2023 Mar 1; 2022 Jul 29. PMID: 35907197.
Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates.Chen B, Ojha DP, Toyonaga T, Tong J, Pracitto R, Thomas MA, Liu M, Kapinos M, Zhang L, Zheng MQ, Holden D, Fowles K, Ropchan J, Nabulsi N, De Feyter H, Carson RE, Huang Y, Cai Z. Eur J Nucl Med Mol Imaging. 2023 Feb 28; 2023 Feb 28. PMID: 36849748.
Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis.Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, DeLima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse CS, Badawy SM, Al Hadidi SA, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh MM, Munshi P, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Blood Adv. 2023 Feb 24; 2023 Feb 24. PMID: 36827681.
Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments anti-tumor activity in melanoma.Tran TT, Caulfield JI, Zhang L, Schoenfeld DA, Djureinovic D, Chiang VL, Oria VO, Weiss SA, Olino K, Jilaveanu LB, Kluger HM. JCI Insight. 2023 Feb 23; 2023 Feb 23. PMID: 36821392.
Dose-Dependent Nuclear Delivery and Transcriptional Repression with a Cell-Penetrant MeCP2.Zhang X, Cattoglio C, Zoltek M, Vetralla C, Mozumdar D, Schepartz A. ACS Cent Sci. 2023 Feb 22; 2023 Feb 3. PMID: 36844491.
Loss to follow-up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group.Puthenpura V, Ji L, Xu X, Roth ME, Freyer DR, Frazier AL, Marks AM, Pashankar FD. Cancer. 2023 Feb 22; 2023 Feb 22. PMID: 36813754.
Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms.Chhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan WY, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood LD, Iacobuzio-Donahue C, Wolfgang CL, Kunstman JW, Salem RR, Farrell JJ, Ahuja N. Clin Epigenetics. 2023 Feb 20; 2023 Feb 20. PMID: 36803844.
Fragment Coupling Approach to Diaporthein B.Hsu IT, Herzon SB. J Org Chem. 2023 Feb 17; 2023 Feb 3. PMID: 36737056.
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.Abu-Khalaf MM, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov WM, Mita MM, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin EF, Pierobon M. NPJ Precis Oncol. 2023 Feb 16; 2023 Feb 16. PMID: 36797347.
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.Hill BL, Graf RP, Shah K, Danziger N, Lin DI, Quintanilha J, Li G, Haberberger J, Ross JS, Santin AD, Slomovitz B, Elvin JA, Eskander RN. Int J Gynecol Cancer. 2023 Feb 15; 2023 Feb 15. PMID: 36750267.
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.Frumm SM, Shimony S, Stone RM, DeAngelo DJ, Bewersdorf JP, Zeidan AM, Stahl M. Blood Rev. 2023 Feb 12; 2023 Feb 12. PMID: 36805300.
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.Wang Y, Malik S, Suh HW, Xiao Y, Deng Y, Fan R, Huttner A, Bindra RS, Singh V, Saltzman WM, Bahal R. Sci Adv. 2023 Feb 10; 2023 Feb 8. PMID: 36753549.
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. J Clin Oncol. 2023 Feb 10. PMID: 36750016.
Reply to S. Raoof.Dbouk M, Katona BW, Brand RE, Chak A, Syngal S, Farrell JJ, Kastrinos F, Stoffel EM, Canto MI, Goggins M. J Clin Oncol. 2023 Feb 10; 2022 Oct 31. PMID: 36315911.
How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines.El Chaer F, Hourigan CS, Zeidan AM. Blood. 2023 Feb 9; 2023 Feb 9. PMID: 36758209.
Survival Outcomes of Optimally Treated Colorectal Metastases: The Importance of R0 Status in Surgical Treatment of Hepatic and Peritoneal Surface Disease.Solsky I, Moaven O, Valenzuela CD, Lundy M, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha C, Zarandi NP, Dourado J, Russell G, Levine EA, Votanopoulos KI, Shen P. Ann Surg Oncol. 2023 Feb 8; 2023 Feb 8. PMID: 36754944.
Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality.Hu Z, Chen PH, Li W, Douglas T, Hines J, Liu Y, Crews CM. J Am Chem Soc. 2023 Feb 8; 2023 Feb 8. PMID: 36753634.
Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials.LoRusso PM, Freidlin B. J Natl Cancer Inst. 2023 Feb 8. PMID: 36448688.
Atropisomers: Synthesis, Analysis, and Applications.Kozlowski MC, Miller SJ, Perreault S. Acc Chem Res. 2023 Feb 7. PMID: 36748251.
Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.Chow RD, Michaels T, Bellone S, Hartwich TMP, Bonazzoli E, Iwasaki A, Song E, Santin AD. Cancer Discov. 2023 Feb 6. PMID: 36301137.
Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.Miguez S, Lee RY, Chan AX, Demkowicz PC, Jones BSCL, Long CP, Abramson DH, Bosenberg M, Sznol M, Kluger H, Goldbaum MH, Francis JH, Pointdujour-Lim R, Bakhoum MF. Ophthalmology. 2023 Feb 4; 2023 Feb 4. PMID: 36739981.
Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Hepatology. 2023 Feb 3; 2023 Feb 3. PMID: 36724446.
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P. Cancer Res Commun. 2023 Feb; 2023 Feb 2. PMID: 36968138.
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen DT, Buckstein RJ, Brunner AM, Carraway HE, Daver NG, Díez-Campelo M, de Witte TM, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner MC, Komrokji RS, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz GF, Scheinberg P, Stauder R, Van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Blood. 2023 Feb 1; 2023 Feb 1. PMID: 36724453.
An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.Venugopal S, Xie Z, Zeidan AM. Expert Rev Hematol. 2023 Feb; 2023 Feb 8. PMID: 36718500.
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.Bhatia A, Burtness B. Drugs. 2023 Feb; 2023 Jan 16. PMID: 36645621.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.Germing U, Fenaux P, Platzbecker U, Buckstein R, Santini V, Díez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji RS, Zeidan AM, Garcia-Manero G. Ann Hematol. 2023 Feb; 2023 Jan 13. PMID: 36635381.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.Manavella DD, McNamara B, Harold J, Bellone S, Hartwich TMP, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa MS, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Dottino PR, Choi J, Alexandrov LB, Buza N, Hui P, Santin AD. Gynecol Oncol. 2023 Feb; 2022 Dec 14. PMID: 36525930.
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia.Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Stahl M, Stein EM, Huntington SF, Zeidan AM. Leuk Lymphoma. 2023 Feb; 2022 Dec 9. PMID: 36493798.
Advances in antibody-drug conjugates for gynecologic malignancies.Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD. Curr Opin Obstet Gynecol. 2023 Feb 1; 2022 Dec 8. PMID: 36484278.
Simulating time-to-event data subject to competing risks and clustering: A review and synthesis.Meng C, Esserman D, Li F, Zhao Y, Blaha O, Lu W, Wang Y, Peduzzi P, Greene EJ. Stat Methods Med Res. 2023 Feb; 2022 Nov 22. PMID: 36412111.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie R, Odenike O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng WH, Zhou Y, Hoffman D, Harb JG, Potluri J, Garcia-Manero G. Am J Hematol. 2023 Feb; 2022 Nov 10. PMID: 36309981.
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. J Clin Oncol. 2023 Feb 1; 2022 Oct 18. PMID: 36256912.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. J Clin Oncol. 2023 Feb 1; 2022 Oct 11. PMID: 36219809.
Clinical care in hepatocellular carcinoma: A mixed methods assessment of experiences and challenges of oncology professionals.Jacobs G, Boyle DA, El-Serag HB, Lewandowski RJ, Stein SM, Lazure P, McFadden P. Cancer Med. 2023 Feb; 2022 Sep 15. PMID: 36106593.
An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach: Analysis of Data From a Tertiary Care Medical Center.Wang JD, Sebastian C, Walther Z, Suresh T, Lacy J, Zhang X, Jain D. Arch Pathol Lab Med. 2023 Feb 1. PMID: 35512224.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. J Clin Oncol. 2023 Jan 31; 2023 Jan 31. PMID: 36720083.
Melanoma in pregnancy.Czeyda-Pommersheim F, Kluger H, Langdon J, Menias C, VanBuren W, Leventhal J, Baumann R Jr, Revzin M. Abdom Radiol (NY). 2023 Jan 31; 2023 Jan 31. PMID: 36719425.
Macrophage-Derived 25-Hydroxycholesterol Promotes Vascular Inflammation, Atherogenesis, and Lesion Remodeling.Canfrán-Duque A, Rotllan N, Zhang X, Andrés-Blasco I, Thompson BM, Sun J, Price NL, Fernández-Fuertes M, Fowler JW, Gómez-Coronado D, Sessa WC, Giannarelli C, Schneider RJ, Tellides G, McDonald JG, Fernández-Hernando C, Suárez Y. Circulation. 2023 Jan 31; 2022 Nov 23. PMID: 36416142.
Catalytic Asymmetric Synthesis of Atropisomeric N-Aryl 1,2,4-Triazoles.Choi S, Guo MC, Coombs GM, Miller SJ. J Org Chem. 2023 Jan 27; 2023 Jan 27. PMID: 36705994.
Top advances of the year: Head and neck cancer.Verma A, Burtness B. Cancer. 2023 Jan 24; 2023 Jan 24. PMID: 36692372.
Epstein-Barr virus-associated primary intracranial leiomyosarcoma in an immunocompetent patient: illustrative case.Tabor JK, Lei H, Morales-Valero SF, O'Brien J, Gopal PP, Erson-Omay EZ, Fulbright RK, Moliterno J. J Neurosurg Case Lessons. 2023 Jan 23; 2023 Jan 23. PMID: 36692065.
Considerations for Drug Development in Myelodysplastic Syndromes.Sekeres MA, Kim N, DeZern AE, Norsworthy KJ, Garcia JS, de Claro RA, Theoret MR, Jen EY, Ehrlich LA, Zeidan AM, Komrokji RS. Clin Cancer Res. 2023 Jan 23; 2023 Jan 23. PMID: 36688922.
Generation of Stable Epithelial-Mesenchymal Hybrid Cancer Cells with Tumorigenic Potential.Tedja R, Alvero AB, Fox A, Cardenas C, Pitruzzello M, Chehade H, Bawa T, Adzibolosu N, Gogoi R, Mor G. Cancers (Basel). 2023 Jan 22; 2023 Jan 22. PMID: 36765641.
Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort.Power S, Bickel K, Chen RC, Chiang AC, Garrett-Mayer L, Makhoul I, Mougalian SS, Shapiro CL, Siegel R, Smith C, Rocque GB, Kozlik MM, Crist STS, Kamal A. JCO Oncol Pract. 2023 Jan 20; 2023 Jan 20. PMID: 36669136.
Author Correction: Head and neck squamous cell carcinoma.Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Nat Rev Dis Primers. 2023 Jan 19; 2023 Jan 19. PMID: 36658129.
Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.Di M, Long JB, Kothari SK, Sethi T, Zeidan AM, Podoltsev NA, Shallis RM, Wang R, Ma X, Huntington SF. Haematologica. 2023 Jan 19; 2023 Jan 19. PMID: 36655436.
Life mimics art.Venkatachalapathy M, Crews CM. Cell Res. 2023 Jan 16; 2023 Jan 16. PMID: 36646761.
Gut colonization by Bacteroides requires translation by an EF-G paralog lacking GTPase activity.Han W, Peng BZ, Wang C, Townsend GE 2nd, Barry NA, Peske F, Goodman AL, Liu J, Rodnina MV, Groisman EA. EMBO J. 2023 Jan 16; 2022 Dec 6. PMID: 36472247.
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. Cancer. 2023 Jan 15; 2022 Nov 17. PMID: 36397669.

2022

Cytochrome P450 3A4 suppression by epimedium and active compound kaempferol leads to synergistic anti-inflammatory effect with corticosteroid.Li K, Yu XH, Maskey AR, Musa I, Wang ZZ, Garcia V, Guo A, Yang N, Srivastava K, Dunkin D, Li JX, Guo L, Cheng YC, Yuan H, Tiwari R, Li XM. Front Pharmacol. 2022; 2023 Jan 30. PMID: 36793921.